Recent Updates
Recently added Catalysts
BNTX Negative Sentiment Score: 20/100

BioNTech SE investors: Please contact the Portnoy Law Firm to recover your losses; March 12, 2024 deadline

Key Takeaway: A lawsuit has been initiated by the Portnoy Law Firm on behalf of investors who purchased BioNTech SE securities between March 30, 2022, and October 13, 2023. The allegations suggest that BioNTech did not transparently communicate issues related to the demand for their COVID-19 vaccine, Comirnaty, and had excess inventory that was mismanaged. Investors are invited to contact the law firm to explore options for recovering potential losses, as the case claims that misleading optimistic statements were made regarding the company's performance and future prospects.

Market Sentiment Analysis

CONCERNS & RISKS

  • A lawsuit has been filed against BioNTech for not disclosing key issues to investors.
  • The allegations include exaggerating the demand and commercial potential of Comirnaty.
  • BioNTech faces risks of inventory write-offs due to excessive stockpiling of vaccine materials.
  • The company’s optimistic statements about business prospects were misleading.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) investors that a lawsuit was filed on behalf of investors that purchased B. Riley securities between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The lawsuit alleges that during the specified period, the defendants did not inform investors about the following issues: (1) BioNTech had exaggerated the demand and commercial potential of Comirnaty; (2) BioNTech and/or Pfizer had accumulated an excessive stockpile of raw materials for Comirnaty, as well as doses of the COVID-19 vaccine tailored to variants other than XBB.1.5, which were produced on a speculative basis; (3) as a result, BioNTech faced a heightened risk of having to write off substantial inventory and incur related charges for Comirnaty; and (4) consequently, the optimistic statements made by the defendants regarding the company’s business, operational performance, and future prospects were significantly misleading and/or lacked a solid factual foundation at all times in question.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

How can investors contact the Portnoy Law Firm?

Investors can reach the Portnoy Law Firm at 310-692-8883 or via email at lesley@portnoylaw.com.

What is the lawsuit against BioNTech about?

The lawsuit claims BioNTech misled investors about the demand for Comirnaty and inventory risks.

What time period does the lawsuit cover?

The lawsuit covers securities purchased between March 30, 2022, and October 13, 2023.

Is there a cost to evaluate my case with the Portnoy Law Firm?

No, the Portnoy Law Firm offers a complimentary case evaluation for interested investors.

Who can I contact for more information about my legal rights?

You can contact attorney Lesley F. Portnoy for information regarding your legal rights.

Last updated: Mar 4, 2024